Risk Factors for Mortality in Patients with Candidemia and the Usefulness of a Candida Score
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Although effective antifungal agents for the treatment of candidemia have recently been introduced, the mortality rate attributed to candidemia remains high (19~49%). Objective: This study aimed at evaluating the risk factors for mortality in patients with candidemia and at assessing the usefulness of a Candida Score in these patients. Methods: A cohort of patients with positive blood cultures for Candida species was retrospectively analyzed at Soonchunhyang University Hospital, a 750-bed teaching hospital, from May 2003 to February 2012. The Candida Score was calculated by assigning 1 point to any of total parenteral nutrition (TPN),surgery, or multifocal Candida species colonization, and 2 points to severe sepsis. Results: Sixty patients (68.3% men; mean age (standard deviation [SD]), 61.8 [18.9] years) with blood cultures positive for Candida species were identified. Most patients had been admitted to an intensive care unit (48 [80%]), were receiving broad-spectrum antibiotics (37 [61.7%]), had TPN (29[48.3%]), had diabetes mellitus (23 [38.3%]), and were receiving hemodialysis (10 [16.7%]). The mean (SD) Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 19.60 (8.8). Twentythree patients (38.3%) had a Candida Score >2.5. The Candida species causing infection included C. albicans (41 [68.3%]), C. tropicalis (7 [11.7%]), C. parapsilosis (4 [6.7%]), C. krusei (3 [5%]), C. glabrata (3 [5%]), C. guilliermondii (1 [1.7%]), and C. catenulata (1 [1.7%]). Only 32 patients (53.3%)received adequate antifungal treatment. The candidemia-related mortality rate was 61.7% (n = 37patients). Multivariate logistic regression analysis demonstrated that a high APACHE II score (adjusted odds ratio [aOR], 1.2; 95% confidence interval [95% CI], 1.0~1.3; p = 0.01), presence of a malignancy (aOR, 14.8; 95% CI, 2.5~88.0; p = 0.003), and treatment with an antifungal agent (aOR, 0.2; 95% CI,0.0~1.0; p = 0.048) were associated with disease-related mortality. Conclusion: The risk factors for mortality in patients with candidemia are a high APACHE II scores and presence of a malignancy. However, the sensitivity of the Candida Score was not high (38.3%). New methods to rapidly identify candidemia and avoid delays in treatment with appropriate antifungal therapy are needed.
Abstract
Background: Although effective antifungal agents for the treatment of candidemia have recently been introduced, the mortality rate attributed to candidemia remains high (19~49%). Objective: This study aimed at evaluating the risk factors for mortality in patients with candidemia and at assessing the usefulness of a Candida Score in these patients. Methods: A cohort of patients with positive blood cultures for Candida species was retrospectively analyzed at Soonchunhyang University Hospital, a 750-bed teaching hospital, from May 2003 to February 2012. The Candida Score was calculated by assigning 1 point to any of total parenteral nutrition (TPN),surgery, or multifocal Candida species colonization, and 2 points to severe sepsis. Results: Sixty patients (68.3% men; mean age (standard deviation [SD]), 61.8 [18.9] years) with blood cultures positive for Candida species were identified. Most patients had been admitted to an intensive care unit (48 [80%]), were receiving broad-spectrum antibiotics (37 [61.7%]), had TPN (29[48.3%]), had diabetes mellitus (23 [38.3%]), and were receiving hemodialysis (10 [16.7%]). The mean (SD) Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 19.60 (8.8). Twentythree patients (38.3%) had a Candida Score >2.5. The Candida species causing infection included C. albicans (41 [68.3%]), C. tropicalis (7 [11.7%]), C. parapsilosis (4 [6.7%]), C. krusei (3 [5%]), C. glabrata (3 [5%]), C. guilliermondii (1 [1.7%]), and C. catenulata (1 [1.7%]). Only 32 patients (53.3%)received adequate antifungal treatment. The candidemia-related mortality rate was 61.7% (n = 37patients). Multivariate logistic regression analysis demonstrated that a high APACHE II score (adjusted odds ratio [aOR], 1.2; 95% confidence interval [95% CI], 1.0~1.3; p = 0.01), presence of a malignancy (aOR, 14.8; 95% CI, 2.5~88.0; p = 0.003), and treatment with an antifungal agent (aOR, 0.2; 95% CI,0.0~1.0; p = 0.048) were associated with disease-related mortality. Conclusion: The risk factors for mortality in patients with candidemia are a high APACHE II scores and presence of a malignancy. However, the sensitivity of the Candida Score was not high (38.3%). New methods to rapidly identify candidemia and avoid delays in treatment with appropriate antifungal therapy are needed.
참고문헌 (19)
- Peman J, "Current diagnostic approaches to invasive candidiasis in critical care settings", Mycoses, 53, pp.424~433 (2010)
- Wisplinghoff H, "Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study", Clin Infect Dis, 39, pp.309~317 (2004)
- Edmond MB, "Nosocomial bloodstream infections in United States hospitals: a three-year analysis", Clin Infect Dis, 29, pp.239~244 (1999)
- Pappas PG, "A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients", Clin Infect Dis, 37, pp.634~643 (2003)
- Nucci M, "Fungemia in cancer patients in Brazil: predominance of non-albicans species", Mycopathologia, 141, pp.65~68 (1998)
- Wenzel RP, "Nosocomial candidemia: risk factors and attributable mortality", Clin Infect Dis, 20, pp.1531~1534 (1995)
- Blot S, "Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata", J Hosp Infect, 47, pp.308~313 (2001)
- Cornwell EE, 3rd, "The pattern of fungal infections in critically ill surgical patients", Am Surg, 61, pp.847~850 (1995)
- Voss A, "Candidemia in intensive care unit patients: risk factors for mortality", Infection, 25, pp.8~11 (1997)
- 한선숙, "Clinical Characteristics and Risk Factors for Nosocomial Candidemia in Medical Intensive Care Units: Experience in a Single Hospital in Korea for 6.6 Years", Journal of Korean Medical Science, 25(5), pp.671~676 (2010), 대한의학회
- Garey KW, "Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study", Clin Infect Dis, 43, pp.25~31 (2006)
- Morrell M, "Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality", Antimicrob Agents Chemother, 49, pp.3640~3645 (2005)
- Leon C, "A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization", Crit Care Med, 34, pp.730~737 (2006)
- Leon C, "Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study", Crit Care Med, 37, pp.1624~1633 (2009)
- Fraser VJ, "Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality", Clin Infect Dis, 15, pp.414~421 (1992)
- Komshian SV, "Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome", Rev Infect Dis, 11, pp.379~390 (1989)
- Wey SB, "Hospital-acquired candidemia. The attributable mortality and excess length of stay", Arch Intern Med, 148, pp.2642~2645 (1988)
- Rentz AM, "The impact of candidemia on length of hospital stay, outcome, and overall cost of illness", Clin Infect Dis, 27, pp.781~788 (1998)
- 채명종, "Real-time PCR법을 이용한 Candida glabrata의 Azole 내성 유전자 발현 분석:Northern 교잡법과의 비교", 대한의진균학회지, 13(2), pp.43~52 (2008), 대한의진균학회